Detection Technology (DETEC) investor relations material

Executive summary

• Net sales increased 13.5% year-over-year to €25.3 million in Q1 2026, with growth across all business applications and regions.

• EBITA rose to €2.4 million, representing a margin of 9.3%, up from 6.3% in Q1 2025.

• Medical, security, and industrial applications all saw double-digit or strong growth, with EMEIA and Americas regions performing particularly well.

• Material shortages eased, and new product launches in medical CT and detector systems supported performance.

Financial highlights

• Net sales: €25.3 million in Q1 2026, up from €22.2 million in Q1 2025.

• EBITA: €2.4 million (9.3% margin), compared to €1.4 million (6.3%) a year earlier.

• Earnings per share: €0.13, up from €0.05 in Q1 2025.

• Cash flow from operating activities was negative at -€3.4 million, impacted by increased inventories.

• R&D costs were €2.8 million, 11% of net sales.

Outlook and guidance

• Net sales expected to grow year-over-year in Q2 and Q3 2026.

• Medical and security application sales anticipated to increase; industrial sales to grow sequentially but decline year-over-year.

• Medium-term targets: annual sales growth above 10% and EBITA margin of 15%.

• Geopolitical risks, US tariffs, material shortages, and price competition in China remain uncertainties.